Recent developments in geriatric psychopharmacology.
There is a tremendous growing need to address the burden of geriatric psychiatric disorders. Recent developments relevant to geriatric psychiatry have focused on Alzheimers disease (AD), severerefractory depression, and cancerend of life care. This is a non-systematic, narrative review (databases and websites for search PubMed, Google Scholar, Medscape, ClinicalTrials.gov focusing on the last 6 years), and covers developments in disease-modifying therapies for AD, diagnostic radiotracers for AD, medications for neuropsychiatric symptoms of dementia, ketamineesketamine, psychedelics, and cannabinoids. The focus of on-going trials of anti-amyloid agents has been on individuals with very early stage AD several agents are under phase 3 investigation, and aducanumab is under FDA review. Amyloid and tau PET scans have been approved by the FDA to assist in the diagnoses of AD. Promising pharmaceuticals for neuropsychiatric symptoms of dementia include pimavanserin, brexpiprazole, escitalopram, dextromethorphanquinidine, and lithium. Esketamine, although approved for treatment-resistant depression in general adults, failed to demonstrate efficacy in elderly patients in a phase 3 trial. There is preliminary evidence for benefit of psychedelic-assisted psychotherapy in end-of-life and cancer-related depressionanxiety. Evidence for the use of cannabinoids is currently lacking.